Dan P. Zandberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dan P. Zandberg has a total of 343 co-authors. Here are the top co-authors by number of shared publications:
- Robert L. Ferris
UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania
73 shared publications - Jill Walker
AstraZeneca, Cambridge, United Kingdom
32 shared publications - Jérôme Fayette
Medicine Department, Centre Léon Bérard, Lyon, France
32 shared publications - Lillian L. Siu
Princess Margaret Cancer Centre, Toronto, Canada
32 shared publications - Lisa Licitra
Department of Oncology and Hemato-Oncology, University of Milan, Via Santa Sofia 9/1, 20122, Milan, Italy
32 shared publications - Melissa de Los Reyes
AstraZeneca, Gaithersburg, Maryland
32 shared publications
Latest Publications
- Open Access
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1697-1708
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial
PURPOSE: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis, particularly those with human papillomavirus (HPV)–negative disease, in which elevated epidermal growth factor receptor and transforming growth factor-β impair tumor penetration of immune cells and lessen immunotherapy responses. METHODS: We present results from an expansion cohort of a first-in-human phase I/Ib trial (ClinicalTrials.gov identifier: NCT04429542 ) evaluating first-line treatment with ficerafusp alfa 1,500 mg once every week in combination with pembrolizumab 200 mg once every 3 weeks administered intravenously in patients with R/M HNSCC overexpressing PD-L1 (combined positive score ≥1). The primary end point was safety. Secondary end points included objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS). RESULTS: Between February 2022 and April 2023, 42 patients received ≥1 dose of study drug and 39 were included in the efficacy-evaluable set (≥1 postbaseline scan). The median follow-up was 26.3 months. Nineteen of 42 patients (45%) had a grade 3 treatment-related adverse event (TRAE), and one (2%) had a grade 4 TRAE. The most common grade ≥3 TRAEs were anemia (14%) and acneiform dermatitis (12%). In efficacy-evaluable patients with HPV-negative (n = 28) or HPV-positive (n = 11) tumors, confirmed ORRs were 54% (complete response in 21%) and 27%, respectively. In the HPV-negative subgroup, median DOR was 21.7 months (95% CI, 6.0 to not estimable [NE]), median PFS was 9.9 months (95% CI, 4.4 to 22.7), and median OS was 21.3 months (95% CI, 9.9 to NE). CONCLUSION: Ficerafusp alfa plus pembrolizumab demonstrated favorable safety and tolerability with promising antitumor activity in the first-line treatment of R/M HNSCC, particularly in those with HPV-negative tumors.
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1697-1708
Open AccessFicerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial
PURPOSE: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis, particularly those with human papillomavirus (HPV)–negative disease, in which elevated epidermal growth factor receptor and transforming growth factor-β impair tumor penetration of immune cells and lessen immunotherapy responses. METHODS: We present results from an expansion cohort of a first-in-human phase I/Ib trial (ClinicalTrials.gov identifier: NCT04429542 ) evaluating first-line treatment with ficerafusp alfa 1,500 mg once every week in combination with pembrolizumab 200 mg once every 3 weeks administered intravenously in patients with R/M HNSCC overexpressing PD-L1 (combined positive score ≥1). The primary end point was safety. Secondary end points included objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS). RESULTS: Between February 2022 and April 2023, 42 patients received ≥1 dose of study drug and 39 were included in the efficacy-evaluable set (≥1 postbaseline scan). The median follow-up was 26.3 months. Nineteen of 42 patients (45%) had a grade 3 treatment-related adverse event (TRAE), and one (2%) had a grade 4 TRAE. The most common grade ≥3 TRAEs were anemia (14%) and acneiform dermatitis (12%). In efficacy-evaluable patients with HPV-negative (n = 28) or HPV-positive (n = 11) tumors, confirmed ORRs were 54% (complete response in 21%) and 27%, respectively. In the HPV-negative subgroup, median DOR was 21.7 months (95% CI, 6.0 to not estimable [NE]), median PFS was 9.9 months (95% CI, 4.4 to 22.7), and median OS was 21.3 months (95% CI, 9.9 to NE). CONCLUSION: Ficerafusp alfa plus pembrolizumab demonstrated favorable safety and tolerability with promising antitumor activity in the first-line treatment of R/M HNSCC, particularly in those with HPV-negative tumors.
- Top Cited Papers
- 10 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (14) , 1349-1372
Systemic Treatment of Thyroid Cancer: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: A total of 66 publications were identified to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer .
- 10 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (14) , 1349-1372
Top Cited PapersSystemic Treatment of Thyroid Cancer: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: A total of 66 publications were identified to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer .
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose:Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC.Experimental Design:Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment.Results:A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO.Conclusions:BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose:Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC.Experimental Design:Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment.Results:A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO.Conclusions:BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 2. GSEA gene sets with significant nominal p-values and associated ranks, metric, and enrichment score (ES).
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 2. GSEA gene sets with significant nominal p-values and associated ranks, metric, and enrichment score (ES).
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 1. Median gene expression by PTC BRAF-V600E vs BRAF-WT.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 1. Median gene expression by PTC BRAF-V600E vs BRAF-WT.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world overall survival (OS) in patients with BRAF-mut PTC treated with BRAF/MEKi, TKI or IO from Biopsy Date.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world overall survival (OS) in patients with BRAF-mut PTC treated with BRAF/MEKi, TKI or IO from Biopsy Date.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC by Biopsy Date.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC by Biopsy Date.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Correlation of PD-L1 RNA expression and PD-L1 IHC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Correlation of PD-L1 RNA expression and PD-L1 IHC.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC.